X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody. It is being evaluated for the treatment of ABCC6 Deficiency and ENPP1 Deficiency.
Lead Product(s): INZ-701
Therapeutic Area: Genetic Disease Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody. It is being evaluated for the treatment of ABCC6 Deficiency and ENPP1 Deficiency.
Lead Product(s): INZ-701
Therapeutic Area: Genetic Disease Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton.
Lead Product(s): rhENPP1-Fc
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy in development for the treatment of ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).
Lead Product(s): INZ-701
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
The company intends to use the net proceeds to fund advancement of its INZ-701 (rhENPP1-Fc) clinical program, including its ongoing Phase 1/2 trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency, its ongoing Phase 1b trial of INZ-701 for infants with ENPP1 Deficiency.
Lead Product(s): rhENPP1-Fc
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $64.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 01, 2023
Details:
The net proceeds will fund advancement of company's INZ-701 (rhENPP1-Fc) clinical program, including its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency.
Lead Product(s): rhENPP1-Fc
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2023
Details:
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton.
Lead Product(s): INZ-701
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton.
Lead Product(s): INZ-701
Therapeutic Area: Rare Diseases and Disorders Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
INZ-701 is a soluble protein which circulates throughout the body and cleave extracellular ATP into PPi and AMP, a precursor of adenosine. It is being developed for the treatment of ENPP1 and ABCC6 deficiency
Lead Product(s): INZ-701
Therapeutic Area: Cardiology/Vascular Diseases Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
Inozyme Pharma is developing INZ-701, a first-in-class enzyme therapy, to address pathologic mineralization and intimal proliferation which drive morbidity and mortality in these severe diseases. INZ-701 is being developed for the treatment of ENPP1 and ABCC6 Deficiency.
Lead Product(s): INZ-701
Therapeutic Area: Cardiology/Vascular Diseases Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
